WUXI BIO(WXXWY) Prnewswire·2024-08-30 09:18Core Insights - WuXi Biologics has successfully scaled up its proprietary WuXiUI™ platform to 2,000L drug substance GMP manufacturing, achieving a 4-fold productivity improvement compared to traditional methods [1][3] - The utilization of WuXiUI™ and MagniCHO™ cell culture media has led to significant reductions in overall drug substance manufacturing costs [1][2] - The platform demonstrates consistent performance from small scales to large-scale production, confirming its maturity and robustness in biologics production [1][3] Manufacturing Efficiency - The enhanced downstream technology platform has doubled purification processing capacity while maintaining similar impurity removal, resulting in a 50% reduction in downstream processing time and a final drug substance yield of 70% [2] - WuXiUI™ has enabled a 30-50% reduction in the utilization of materials and consumables, leading to decreased waste generation [2][3] - The integration of Raman Process Analytical Technology (PAT) into the manufacturing process has improved operational efficiency and provided real-time automated process control [4] Market Position and Strategy - The WuXiUI™ platform, launched in 2023, enhances productivity for various CHO and other mammalian cell lines, addressing the growing demand for therapeutic proteins and antibodies with lower costs [3] - The company aims to provide clients with more affordable, high-quality biologics, thereby benefiting patients globally [5] - WuXi Biologics supports 742 integrated client projects, including 16 in commercial manufacturing, showcasing its extensive operational capabilities [6] Commitment to Sustainability - WuXi Biologics emphasizes Environmental, Social, and Governance (ESG) responsibilities as a core part of its business strategy, aiming to become a leader in ESG within the biologics CRDMO sector [7] - The company utilizes next-generation biomanufacturing technologies and clean-energy sources to enhance its sustainability efforts [7]